Your browser doesn't support javascript.
loading
Identification of SARS-CoV-2 m6A modification sites correlate with viral pathogenicity.
Liu, Ke; Zhang, Ying-Zi; Yin, Hui; Yu, Lu-Lu; Cui, Jia-Jia; Yin, Ji-Ye; Luo, Chen-Hui; Guo, Cheng-Xian.
Afiliação
  • Liu K; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, China;
  • Zhang YZ; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, China;
  • Yin H; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, China;
  • Yu LL; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, China;
  • Cui JJ; National Clinical Research Center for Geriatric Disorders, China; Department of Geriatric Surgery, Xiangya Hospital, Central South University, China.
  • Yin JY; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, China;
  • Luo CH; Scientific Research Office, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China. Electronic address: lchhr0107@163.com.
  • Guo CX; Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, China. Electronic address: gchxyy@163.com.
Microbes Infect ; 26(1-2): 105228, 2024.
Article em En | MEDLINE | ID: mdl-37734532
It has recently been found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) m6A modifications can affect viral replication and function. However, no studies to date have shown a correlation between SARS-CoV-2 m6A modifications and viral pathogenicity. In this study, we analyzed m6A modification in 2,190,667 SARS-CoV-2 genomic RNAs. m6A modifications of SARS-CoV-2 from different lineages, causing mild or severe COVID-19 and showing breakthrough for different vaccines were analyzed to explore correlations with viral pathogenicity. The results suggested that the presence of more m6A modifications in the SARS-CoV-2 N region (positive strand) correlates with weaker pathogenicity. In addition, we identified three m6A modification sites correlating with weak pathogenicity (924 in ORF1ab, 15,659 in ORF1ab, 28,288 in N, 28,633 in N and 29,385 in N, 29,707 in 3'UTR) and one with strong pathogenicity (74 in 5'UTR). These results provide new information for understanding the prevalence of SARS-CoV-2 and controlling the virus.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenina / SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenina / SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article